IRF5 rs13245639 — The Functional Interferon Brake: A Better Tag for the 5' Protective Haplotype
Your immune system's type I interferon alarm — orchestrated by Interferon Regulatory Factor 5
(IRF5) — is one of the most powerful switches in human innate immunity. When this switch runs
too loud and too long, the result is chronic inflammatory damage seen in systemic lupus
erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis. rs13245639 sits
in the 5' upstream regulatory region of IRF5 at chromosome 7, position 128,927,756 (GRCh38),
and represents one of the most functionally characterized cis-regulatory variants at this locus.
In near-perfect linkage disequilibrium (r²=0.97) with the established protective tag SNP
rs729302, rs13245639 is not merely a proxy — its T allele directly shows allele-specific
transcription factor binding11 transcription factor binding
Detected by electrophoretic mobility shift assay (EMSA): a
technique that reveals whether nuclear proteins bind differently to two alleles of a DNA
sequence and lower IRF5 expression in
reporter gene assays, making it a functional candidate for the protective effect and arguably
a sharper tag on whole-genome sequencing platforms.
The Mechanism
IRF5 operates as a master transcription factor for type I interferon (IFN-α/β) production and for proinflammatory cytokine secretion (IL-12, IL-6, TNF-α) in innate immune cells — monocytes, macrophages, plasmacytoid dendritic cells, and B cells. Overexpression of IRF5 drives the sustained interferon signature characteristic of autoimmune flares. The rs13245639 variant lies within the 5' upstream regulatory architecture of IRF5, approximately 1.15 kilobases from the rs729302 anchor SNP within the same haplotype block.
The functional work by
Alonso-Perez et al. 201322 Alonso-Perez et al. 2013
Identification of three new cis-regulatory IRF5 polymorphisms: in
vitro studies. Arthritis Research & Therapy, 2013
screened 26 candidate cis-regulatory SNPs — selected from 54 genotyped variants across the
IRF5 5' region — for functional activity in lymphoblastoid cells. rs13245639 emerged as one of
only seven that showed reproducible allele-specific differences in EMSA and one of three
(alongside rs729302 itself and an indel at rs11269962) that passed both EMSA and reporter gene
assay criteria. In EMSA experiments, the T allele produced a specific band slowdown (band shift)
compared with the C allele, indicating that one or more nuclear proteins bind preferentially to
the T-allele sequence. The causal transcription factor was not identified — high-throughput
bioinformatic tools performed poorly on this region — but the binding difference is reproducible.
In luciferase reporter gene assays, constructs carrying the major C allele of rs13245639 showed significantly higher expression than constructs with the minor T allele (P<0.05, Wilcoxon matched-pairs test). This is the functionally coherent direction: the C allele drives higher IRF5 transcription, the T allele dampens it. Since the T allele travels with the rs729302-C protective haplotype at r²=0.97, the protective biology is mechanistically consistent — the T allele reduces IRF5 output, softening the interferon alarm and lowering autoimmune drive.
The near-perfect LD (r²=0.97) between rs13245639 and rs729302 in European cohorts means the two variants capture essentially the same haplotype signal. On consumer genotyping arrays that include rs729302, this adds little incremental information. However, on whole-genome sequencing platforms — where both sites are called with equal fidelity — rs13245639 may provide superior functional interpretation because its allele-specific expression difference is directly demonstrated, whereas rs729302 remains a functional tag whose causal status is less certain. The rs729302 signal is partly explained by LD with the CGGGG promoter indel; rs13245639 may tag the same underlying causal architecture from a different angle.
The Evidence
The foundational protective signal at the IRF5 5' locus was established in the landmark
14-cohort European SLE study by Ferreiro-Neira et al. 200733 Ferreiro-Neira et al. 2007
Ann Rheum Dis 2007
66:1338-41, which genotyped 1,383 SLE cases and
1,614 controls. Two independent signals emerged from the IRF5 locus: a 3' susceptibility signal
(tagged by rs10488631, P<10⁻¹⁷) and an opposing 5' protective signal (tagged by rs729302,
P<10⁻⁶). The protective signal persisted after conditioning on the susceptibility signal,
establishing it as a genuine independent effect. Because rs13245639 is in r²=0.97 LD with
rs729302, the T allele directly captures this protective signal.
In rheumatoid arthritis, a meta-analysis of five case-control studies44 meta-analysis of five case-control studies
Han et al. 2009,
J Rheumatol; 6,582 RA cases and 5,375 controls
confirmed that the rs729302-tagged protective allele reduces RA risk (random-effects OR=0.889,
95% CI 0.803–0.977, P=0.015). By virtue of near-perfect LD, the rs13245639-T allele carries
the same protective association in RA.
The functional significance of rs13245639 specifically — its EMSA band shift and its lower luciferase expression — was established in vitro by Alonso-Perez et al. 2013. While in vitro data alone constitute moderate rather than strong evidence for an individual SNP's causal role, the convergence with the strong epidemiological signal from rs729302 (which it tags at r²=0.97) and the mechanistically coherent direction (T allele = lower IRF5 = reduced autoimmune drive) supports a moderate-to-strong overall evidence rating for the protective biology of this locus.
Practical Implications
Carrying one or two copies of the T allele at rs13245639 indicates your IRF5 locus carries partial or full protective regulatory architecture in the 5' upstream region. This is the same biology captured by rs729302-C — if you have results from a genotyping array that includes rs729302, your rs13245639 interpretation is almost certainly concordant (r²=0.97 means fewer than 3% of people would show discordant genotypes between the two sites).
The protective effect is additive per T allele, consistent with the additive inheritance pattern seen at rs729302. Heterozygous CT individuals carry one buffered and one unbuffered copy of the IRF5 5' regulatory region; TT homozygotes carry the protective architecture on both chromosomes. Neither genotype guarantees freedom from autoimmune disease — the IRF5 locus is one component of a multigenic autoimmune risk architecture that includes HLA, PTPN22, STAT4, and other contributors. However, the T allele provides real, documented biological buffering of the interferon overactivation that underlies SLE and RA.
The most important context for this variant is the full IRF5 haplotype picture: individuals who carry rs13245639-T (no susceptibility at the 5' locus) alongside rs10488631-TT (no susceptibility at the 3' locus) have the most comprehensively protected IRF5 regulatory configuration currently characterized.
Interactions
rs13245639 is in near-perfect LD with rs729302 (r²=0.97) and travels on the same protective 5' haplotype block. For practical purposes, genotyping rs13245639 and rs729302 provides redundant information; however, on WGS data both are present and rs13245639's functional annotation makes it a useful confirmatory or primary tag.
The 5' protective haplotype tagged by rs13245639-T opposes the 3' susceptibility haplotype tagged by rs10488631 (documented separately). These two haplotype blocks are functionally independent — individuals can carry any combination of the two, and their net IRF5-driven autoimmune susceptibility reflects the additive contributions from both loci.
At the pathway level, IRF5 interacts with STAT4 (rs7574865), the signal transducer downstream of type I interferon. IRF5 drives IFN production; STAT4 amplifies cellular responsiveness to that IFN. rs13245639-T carriers who also carry the STAT4 non-risk genotype benefit from a dual buffer: reduced interferon production and reduced interferon amplification.